Form 4: CONMED CEO Pat Beyer Granted Equity Awards

CONMED Corporation's President and CEO, Pat Beyer, received significant equity awards, including 28,800 Restricted Stock Units and 68,258 stock options, under the company's 2025 Long-Term Incentive Plan.

Summary

• Pat Beyer, President & CEO of CONMED Corp (CNMD), was granted 28,800 Restricted Stock Units (RSUs) and 68,258 stock options on March 2, 2026.
• Each RSU represents a contingent right to receive one share of CONMED common stock.
• The RSUs will vest over a three-year period: 33% one year after the grant date, 33% in the second year, and 34% in the third year.
• The stock options have an exercise price of $45.79 per share.
• The stock options will vest in equal amounts over a four-year period, with the first 25% vesting one year after the grant date.
• Both awards were granted under the Company's 2025 Long-Term Incentive Plan and have an expiration date of March 2, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies a commitment to executive retention and performance alignment through standard long-term incentive mechanisms. The grants are expected and reflect ongoing compensation strategy.

Positives

• The granting of equity awards to the President & CEO aligns management's interests with those of shareholders, incentivizing long-term performance.
• The awards are part of a structured long-term incentive plan (2025 Long-Term Incentive Plan), indicating a commitment to executive retention and performance.

Negatives

• The issuance of new equity awards, particularly RSUs, can lead to a slight dilution of existing shareholder value upon vesting and conversion to common stock.

Risks

• Future stock price performance could impact the value realized from these equity awards, potentially affecting executive motivation if the stock underperforms.
• The multi-year vesting schedules tie the executive to the company for several years, but also mean the full value of the awards is not immediately realized, creating a potential for future forfeiture if employment ceases.

Future Outlook

The grants are part of a long-term incentive plan, suggesting a focus on future performance and executive retention over the next three to four years, aligning executive interests with long-term shareholder value creation.

Industry Context

StockSavvy.ai notes that granting equity awards like RSUs and stock options is a standard practice in executive compensation across various industries, particularly in medical technology, to incentivize leadership and align their financial interests with the company's long-term success and shareholder returns. The structure of multi-year vesting is typical for retaining key executives.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for slight dilution upon vesting of RSUs and exercise of options, but also increased alignment of CEO's interests with long-term shareholder value.
• Employees: May signal stability in executive leadership and a commitment to long-term incentive programs.

Next Steps

• Vesting of 33% of RSUs one year after the grant date (March 2, 2027).
• Vesting of 25% of stock options one year after the grant date (March 2, 2027).
• Subsequent annual vesting of RSUs over a three-year period.
• Subsequent annual vesting of stock options over a four-year period.

Key Dates

Keywords

CONMED Corp, CNMD, Pat Beyer, President & CEO, Restricted Stock Units, RSUs, Stock Options, Equity Awards, Insider Transaction, Executive Compensation, Long-Term Incentive Plan, Form 4